The peripheral blood mononuclear cells versus purified CD34+ cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis—a randomized single-blinded non-inferiority trial

Table 2 Efficacy outcomes of WBFPS, PFWT, TcPO₂, ABI and TBI over time

	Group	Baseline	P value	1 year	P value	3 years	P value	5 years	P value
WBFPS	PBMNCs	7.60 ± 1.53	0.503	1.08 ± 2.26	0.116	0.79 ± 2.55	0.508	0.78 ± 2.86	0.730
	PCCs	7.28 ± 1.81		2.13 ± 2.38		1.30 ± 2.85		1.04 ± 2.42
PFWT, seconds	PBMNCs	323.7 ± 383.8	0.898	976.1 ± 385.1	0.365	992.7 ± 488.4	0.894	998.2 ± 398.6	0.956
	PCCs	308.8 ± 430.3		870.6 ± 429.8		1010.0 ± 417.4		1004.6 ± 410.3
TcPO₂, mmHg	PBMNCs	21.3 ± 12.4	0.851	28.5 ± 20.7	0.487	29.0 ± 21.2	0.095	29.6 ± 20.2	0.142
	PCCs	20.6 ± 13.7		24.6 ± 18.6		20.2 ± 14.8		22.4 ± 13.2
ABI	PBMNCs	0.554 ± 0.222	0.230	0.692 ± 0.261	0.147	0.617 ± 0.210	0.575	0.723 ± 0.200	0.631
	PCCs	0.472 ± 0.254		0.586 ± 0.247		0.657 ± 0.285		0.692 ± 0.250
TBI	PBMNCs	0.174 ± 0.191	0.252	0.321 ± 0.132	0.085	0.420 ± 0.308	0.407	0.438 ± 0.224	0.836
	PCCs	0.117 ± 0.155		0.268 ± 0.073		0.354 ± 0.246		0.422 ± 0.312

The data are presented as mean ± SD
WBFPS, Wong–Baker Faces Pain Rating Scales; PFWT, pain-free walking time; TcPO₂, transcutaneous oxygen pressure; ABI, ankle-brachial index; TBI, toe-brachial index; PBMNC, peripheral blood mononuclear cell; PCC, purified CD34⁺ cell; SD, standard deviation

ISSN: 1757-6512